MARKET

AMPH

AMPH

Amphastar Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.52
+0.31
+1.80%
After Hours: 17.52 0 0.00% 16:00 03/05 EST
OPEN
17.33
PREV CLOSE
17.21
HIGH
17.57
LOW
17.12
VOLUME
222.28K
TURNOVER
--
52 WEEK HIGH
22.69
52 WEEK LOW
12.33
MARKET CAP
832.27M
P/E (TTM)
130.26
1D
5D
1M
3M
1Y
5Y
Global Isoprenaline Market Growth 2021 Analysis, Latest Trends, Size, Market Share, Revenue and CAGR Status, Forecast to 2025
Mar 05, 2021 (The Expresswire) -- Global “Isoprenaline Market” research report provides up-to-date market information of Isoprenaline market which lets the...
The Express Wire · 1d ago
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
Zacks · 1d ago
Raymond James Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
Raymond James analyst Elliot Wilbur maintained a Hold rating on Amphastar Pharmaceuticals (AMPH) yesterday. The company's shares closed last Tuesday at
SmarterAnalyst · 2d ago
Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Admi...
GlobeNewswire · 02/26 11:01
Insider Trends: Selling By Insiders Endures at Amphastar Pharmaceuticals
MT Newswires · 02/18 19:12
Substance Abuse Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020-2027
Feb 17, 2021 (Market Insight Reports) -- The global substance abuse treatment market size is projected to surpass US$ 16.2 billion by 2027 and expected to...
Market Insight Reports · 02/17 10:10
Insider Trends: Insider Extends 90-Day Selling Trend at Amphastar Pharmaceuticals
MT Newswires · 02/14 22:54
Insider Trends: Insider Sales Add to 90-Day Trend at Amphastar Pharmaceuticals
MT Newswires · 02/09 17:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMPH. Analyze the recent business situations of Amphastar Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMPH stock price target is 21.80 with a high estimate of 24.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 204
Institutional Holdings: 29.68M
% Owned: 62.49%
Shares Outstanding: 47.50M
TypeInstitutionsShares
Increased
42
1.47M
New
26
-482.18K
Decreased
53
1.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Operating Officer/Director
Mary Luo
President/Chief Executive Officer/Chief Scientific Officer/Director
Jack Zhang
Chief Financial Officer/Senior Vice President/Treasurer
William Peters
Executive Vice President
Rong Zhou
Senior Vice President/Director of Sales/Director of Marketing/Secretary
Jacob Liawatidewi
Lead Director/Independent Director
Richard Prins
Director
Diane Gerst
Independent Director
Richard Koo
Independent Director
Howard Lee
Independent Director
Floyd Petersen
Independent Director
Michael Zasloff
No Data
About AMPH
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Webull offers kinds of Amphastar Pharmaceuticals Inc stock information, including NASDAQ:AMPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMPH stock methods without spending real money on the virtual paper trading platform.